Centessa Pharmaceuticals' Q3 Loss Widens-March 2024-www.financetom.com

Centessa Pharmaceuticals' Q3 Loss Widens

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Centessa Pharmaceuticals' Q3 Loss Widens

Nov 12, 2024 6:14 AM

08:49 AM EST, 11/12/2024 (MT Newswires) -- Centessa Pharmaceuticals ( CNTA ) reported a Q3 loss Tuesday of $0.37 per diluted share, wider than a loss of $0.40 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.41.

As of September 30, cash and cash equivalents were $518.4 million, which is expected to fund operations into mid-2027.

Previous page： Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Intensifying Trade War Next page： Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Intensifying Trade War

Mar 31, 2025

08:46 AM EDT, 03/31/2025 (MT Newswires) -- The broad market exchange-traded fund SPDR S&P 500 ETF Trust ( SPY ) was down 1.1% and the actively traded Invesco QQQ Trust (QQQ) retreated 1.5% in Monday's premarket activity amid an intensifying trade war expected to escalate further after tariff announcements in the prior week. US stock futures were also lower, with...

Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment

Mar 31, 2025

08:59 AM EDT, 03/31/2025 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said late Friday that the US Food and Drug Administration approved Qfitlia, a therapy designed to lower antithrombin, a protein inhibiting blood clotting. The company said Qfitlia is approved for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients with hemophilia A or B....

Nouveau Monde Graphite 2024 Net Loss Widens

Mar 31, 2025

08:58 AM EDT, 03/31/2025 (MT Newswires) -- Nouveau Monde Graphite ( NMG ) was 2.7% higher at last look Monday in NYSE pre-market trading after reporting a higher net loss for 2024, but a narrower loss per share. The company reported a 2024 net and comprehensive loss of $73.3 million, or $0.71 per share, compared to a 2023 net and...

Dow, X-Energy Reactor Submit Building Permit Application for Texas Nuclear Plant Project

Mar 31, 2025

08:59 AM EDT, 03/31/2025 (MT Newswires) -- Dow (DOW) and X-Energy Reactor said Monday they have submitted a construction permit application to the Nuclear Regulatory Commission for a proposed advanced nuclear reactor in Seadrift, Texas. The proposed advanced small modular reactor project is being developed by Dow's Long Mott Energy to provide Dow's Seadrift Operations manufacturing site electrical power and...